.png){kind=icon}
.png){kind=icon}
Return
Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck
.png){kind=icon}
OA
AI
C
A
P
I
A
A
R
V
K
I
S
N
C
J
H
R
B
S
E
V
DOI：10.1016/j.ctrv.2026.103175.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Standardizing endpoints in nIO is essential to improve comparability across resectable HNSCC trials. • Harmonized response criteria (%RVT-based MPR/pCR, separate T/N assessment) will enhance treatment evaluation accuracy. • Translational biomarkers should support personalized nIO strategies and safe response-adapted interventions.
Keywords:
Neoadjuvant immunotherapy
Head and neck squamous cell carcinoma
Pathologic response criteria
Biomarker integration
Trial design standardization
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
No organization information available
Cited Papers